Aggregator

Science, Volume 387, Issue 6736, Page 838-839, February 2025.

Science, Volume 387, Issue 6736, Page 902-902, February 2025.

Science, Volume 387, Issue 6736, Page 880-885, February 2025.

Science, Volume 387, Issue 6736, Page 845-850, February 2025.

Science, Volume 387, Issue 6736, Page 869-873, February 2025.

Science, Volume 387, Issue 6736, Page 885-892, February 2025.

Science, Volume 387, Issue 6736, Page 874-880, February 2025.

Science, Volume 387, Issue 6736, Page 892-900, February 2025.

Science, Volume 387, Issue 6736, Page 864-869, February 2025.

Science, Volume 387, Issue 6736, Page 833-833, February 2025.

Science, Volume 387, Issue 6736, Page 832-832, February 2025.

The latest in science and policy

Stamp-size devices running machine learning models are tackling agricultural, health, and conservation problems in resource-poor regions

“Exceptional” fossil collections housed by the Paleontological Research Institute risk being orphaned

Here’s the story behind the billions in payments to institutions with research grants that NIH wants to cut

Alzheimer's disease (AD) is predominantly the most recurring and devastating neurological condition among the elderly population, characterized by the accumulation of amyloid-β (Aβ) and phosphorylated tau proteins, and is accompanied by progressive decline of learning and memory. Due to its complex and multifactorial etiology, a wide variety of therapeutic interventions have been developed. Despite constant advancements in the field, effective treatments that ameliorate the severity of...

Repurposed drugs provide a rich source of potential therapies for Alzheimer's disease (AD) and other neurodegenerative disorders (NDD). Repurposed drugs have information from non-clinical studies, phase 1 dosing, and safety and tolerability data collected with the original indication. Computational approaches, "omic" studies, drug databases, and electronic medical records help identify candidate therapies. Generic repurposed agents lack intellectual property protection and are rarely advanced to...

Alzheimer's disease (AD) is predominantly the most recurring and devastating neurological condition among the elderly population, characterized by the accumulation of amyloid-β (Aβ) and phosphorylated tau proteins, and is accompanied by progressive decline of learning and memory. Due to its complex and multifactorial etiology, a wide variety of therapeutic interventions have been developed. Despite constant advancements in the field, effective treatments that ameliorate the severity of...

Aging populations worldwide face an increasing burden of age-related chronic conditions, necessitating a deeper understanding of the underlying mechanisms. Purine metabolism has emerged as a crucial player in the pathophysiology of aging, affecting various tissues and organs. Dysregulation of purine metabolism, particularly alterations in extracellular adenosine levels and adenosine receptor signaling, contributes to age-related musculoskeletal problems, cardiovascular diseases, inflammation,...

A fundamental challenge for cancer vaccines is to generate long-lived functional T cells that are specific for tumour antigens. Here we find that mRNA-lipoplex vaccines against somatic mutation-derived neoantigens may solve this challenge in pancreatic ductal adenocarcinoma (PDAC), a lethal cancer with few mutations. At an extended 3.2-year median follow-up from a phase 1 trial of surgery, atezolizumab (PD-L1 inhibitory antibody), autogene cevumeran¹ (individualized neoantigen vaccine with...